We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urinary Pathogen Resistance Increased Post Kidney Transplant

By LabMedica International staff writers
Posted on 31 May 2017
A urinary tract infection (UTI) is the most common complication after kidney transplantation and it can cause severe sepsis and transplant loss. More...
Emergence of drug resistance among gram-negative urinary pathogens is the current challenge for urinary tract infection treatment after kidney transplantation.

The incidence of drug-resistant urinary pathogens seems to be increasing and has become a rising therapeutic challenge for clinicians. The antibiotic exposure after kidney transplantation is elevated due to treatment of asymptomatic bacteriuria (ASB) and pneumocystis pneumonia (PCP) prophylaxis.

Scientists at the University Hospital Essen analyzed the antimicrobial susceptibility of gram-negative urinary pathogens after kidney transplantation from 2009 to 2012 at their Transplant Outpatient Clinic. Kidney transplant patients received regular follow up examinations after transplantation. Midstream urines were examined for bacteriuria at each follow up visit. From 2009 to 2012 a large number of 15,741 urine samples were obtained from 859 patients (324 (38%) male, 535 (62%) female).

Samples were cultured using standard media with semi quantification. Cultured bacteria were identified by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) and susceptibility testing was performed using the VITEK system. Patients suffering UTI or ASB got empirical treatment according to the local UTI treatment strategy. All patients were treated with low-dose trimethoprim-sulfamethoxazole for pneumocystis (PCP) prophylaxis for at least six month after transplantation.

The team reported that the most frequently detected gram-negative bacteria were Escherichia coli, 1,109 (37%), Klebsiella spp. 242 (8%) and Pseudomonas aeruginosa 136 (4.5%). Klebsiella spp. showed a significant increase of resistance to trimethoprim-sulfamethoxazole by 19%, ciprofloxacin by 15% and ceftazidime by 17%. E.coli and P. aeruginosa isolates presented no significant differences of antimicrobial susceptibility to the analyzed antibiotics. In 51 renal transplant patients, urosepsis due to gram-negative pathogens (E.coli, Klebsiella spp., and P. aeruginosa) was diagnosed from 2009 to 2012.

The authors concluded that there was an increase of antimicrobial resistance to commonly used antibiotic agents among gram-negative uropathogens isolated from kidney transplant recipients during an observation period of four years. Antimicrobial resistance of Klebsiella spp. increased significant to trimethoprim-sulfamethoxazole, ciprofloxacin and ceftazidime. The study was published on May 19, 2017, in the journal BMC Nephrology.


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.